+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 101 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating CGT9486 bezuclastinib in an open-label Phase 2 study for patients with Advanced Systemic Mastocytosis AdvSM, including Aggressive Systemic Mastocytosis ASM, Systemic Mastocytosis with an Associated Hematologic Neoplasm SM-AHN, and Mast Cell Leukemia MCL. The study aims to assess the safety, efficacy, pharmacokinetics, and pharmacodynamics of bezuclastinib as a single agent in these conditions. Participants receive bezuclastinib tablets orally, taken continuously in 28-day cycles. The study has two parts Part I focuses on identifying clinically active and tolerable doses of bezuclastinib, while Part II determines the drugs efficacy by measuring the modified IWG Objective Response Rate ORR and confirming the exposure-response relationship. Treatment and evaluation continue for up to 18 months. During the study, participants undergo assessments including laboratory tests, imaging to measure spleen and liver volume, and evaluation of mutation allele burden, serum tryptase, and histopathologic changes in blood and bone marrow. Safety is monitored through adverse event reporting. The study measures duration and time to response, progression-free survival, and overall survival. Participants are involved in regular monitoring throughout the treatment period extending up to 18 months.

Age: 18Years +All GendersPhase 2
42 locations
S

Actively Recruiting

Researchers are conducting a Phase 01, First-in-Human study to assess the safety and tolerability of 177Lu-RAD204, a radiolabelled antibody targeting PD-L1, in participants with selected metastatic solid tumors. The study aims to find the maximum tolerated dose or recommended dose for future research and will also study how the drug distributes in the body, its radiation exposure, and early signs of anti-tumor activity. During the screening period of up to 4 weeks, participants receive a low imaging dose of 177Lu-RAD204 to evaluate dosimetry and confirm tumor lesions. In the treatment phase, participants receive escalating doses of 177Lu-RAD204 every 6 weeks, potentially across multiple cycles if clinical benefit and safety allow. An additional unlabeled RAD204 may be given to improve the drugs targeting of tumor tissue over healthy organs. Participants will undergo assessments including imaging scans, safety monitoring, and evaluation of tumor response. Researchers will measure safety and tolerability at 6-week intervals along with radiation dosimetry and preliminary anti-tumor effects. The study includes detailed monitoring of side effects, organ function, and disease status, continuing as long as participants benefit and meet safety criteria, with expected study completion by December 2027.

Age: 18Years +All GendersEarly Phase 1
6 locations
E

Actively Recruiting

Researchers are evaluating a study medicine called MK-1045 in adults with systemic lupus erythematosus SLE or rheumatoid arthritis RA. This phase 1 clinical trial aims to learn about the safety and how well people tolerate MK-1045 when given at different dose levels. The study is sponsored by Merck Sharp & Dohme LLC and focuses on treatment outcomes for these autoimmune conditions. Participants will receive MK-1045 through intravenous IV infusion in varying ways depending on their study group. Some will get a single IV dose at different dose levels, while others will receive three step-up doses over a 3-week interval, progressing from a prime dose to a target dose. The study includes dose escalation panels and an optional dose expansion phase for further evaluation. During the study, participants will be monitored for adverse events up to 52 weeks. Researchers will assess the number of participants experiencing side effects or discontinuing the drug due to side effects. Blood tests will measure MK-1045 levels and the effect on peripheral B cell counts at specific times. This detailed monitoring helps understand the drugs safety, pharmacokinetics, and pharmacodynamics throughout the trial duration.

Age: 18Years - 75YearsAll GendersPhase 1
21 locations
E

Actively Recruiting

Researchers are evaluating the safety, effectiveness, best dose, and how the body processes a drug called BNT326 alone and combined with other immunotherapies in people with advanced solid tumors. These tumors are either metastatic, recurrent, or have progressed despite prior treatments. The study includes multiple specific tumor types and is divided into two parts, each enrolling participants independently to assess BNT326 alone or with other drugs like pumitamig. Participants in Part 1 receive BNT326 alone in different groups based on their tumor type, including cutaneous melanoma, non-small cell lung cancer, rare melanomas, cervical cancer, and other solid tumors. Part 2 studies BNT326 alone or combined with pumitamig for various cancers such as melanoma, breast cancer, gastric cancer, colorectal cancer, and cervical cancer. Some groups involve random assignment to different dose levels, while others do not. Treatments are given via intravenous infusion or oral administration depending on the drug. Participants undergo a screening period followed by treatment lasting up to 24 months or until disease progression, consent withdrawal, study end, or unacceptable side effects. After treatment, there are safety and efficacy follow-up periods, plus long-term survival tracking, with total involvement lasting about 38 months for Part 1 and 48 months for Part 2. Researchers monitor side effects, tumor response, survival, and drug levels in the blood to assess safety and activity of the treatments.

Age: 18Years +All GendersPhase 1Phase 2
77 locations
P

Actively Recruiting

Researchers are evaluating ONM-501, a drug given as intratumoral injections, alone and in combination with cemiplimab, an immune checkpoint inhibitor, in patients with advanced solid tumors and lymphomas. This phase 1 study aims to find the maximum tolerated dose, minimum effective dose, and recommended dose for expansion of ONM-501. The study includes patients with various advanced cancers who have no alternative standard therapies available. The trial has three parts monotherapy dose escalation, combination therapy dose finding, and combination therapy dose expansion. ONM-501 is given once per week for three weeks followed by three weeks off, in 21-day cycles. Cemiplimab is given intravenously every three weeks during the combination phases. Dose escalation uses special methods to gradually increase doses, and after doses are established, patients will enroll in expansion cohorts for specific tumor types. Participants will have regular assessments including monitoring for side effects, blood tests to measure drug levels, and evaluation of tumor response over up to 24 months. Researchers will track treatment-emergent adverse events, dose-limiting toxicities, and serious adverse events. Outcomes such as objective response rate, duration of response, progression-free survival, and overall survival will also be recorded. The study involves close safety monitoring and follow-up throughout the treatment and observation periods.

Age: 18Years +All GendersPhase 1
16 locations
F

Actively Recruiting

Researchers are evaluating the safety and effectiveness of the WiSE CRT System combined with an intracardiac pacemaker to deliver completely leadless cardiac resynchronization therapy CRT for patients with heart failure. This study is a single-arm, prospective, multicenter, observational trial designed to assess this novel device system that provides left ventricular pacing along with right ventricular pacing for biventricular stimulation. Participants receive the WiSE CRT System implanted to provide left ventricular pacing in combination with an existing system that provides right ventricular pacing. Together, these devices deliver biventricular pacing to the heart. The study follows a single treatment group where WiSE System therapy is turned on alongside guideline-directed medical therapy. The trial collects data over a period that includes assessments at 1 month and 6 months after implantation. During the study, participants will be monitored for device and procedure-related complications, and evaluated with electrocardiograms to confirm biventricular capture at 1 and 6 months. Additional measures include changes in heart function such as ejection fraction and left ventricular volume, as well as improvements in heart failure symptoms and physical capacity using the New York Heart Association NYHA class and six-minute walk test at 6 months. The total participation duration extends up to 6 months, with safety and effectiveness closely observed throughout.

Age: 22Years +All GendersPhase Not Applicable
4 locations
O

Actively Recruiting

Researchers are evaluating the safety, side effects, how the body processes HH160, and its early anticancer activity when given alone or with other cancer treatments in adults with advanced or metastatic solid tumors. This phase 1 trial aims to find the recommended dose for future studies. It includes various tumor types such as lung, liver, colorectal, breast, and other cancers. Participants will receive HH160 through intravenous infusion on either a 14-day or 21-day cycle. The study has multiple parts dose escalation to find tolerable levels, safety expansion at those doses, and dose expansion where HH160 is given alone or with chemotherapy. The trial is expected to last about four years, with treatment and follow-up each lasting about 6 to 12 months. During the study, participants will have regular safety checks, laboratory tests, and imaging to measure tumor response according to RECIST criteria. Researchers will monitor side effects, drug levels in the body, immune response, and how well the tumors respond. The main outcomes include treatment-emergent adverse events, maximum tolerated dose, recommended phase 2 dose, and overall tumor response over up to two years.

Age: 18Years - 75YearsAll GendersPhase 1
3 locations
P

Actively Recruiting

Researchers are evaluating the safety, tolerability, and preliminary effectiveness of IMP1734, a PARP1 selective inhibitor, in people with advanced solid tumors. This study includes patients with breast cancer, metastatic prostate cancer, ovarian cancer, and other solid tumors who have previously received certain treatments. The goal is to find an optimal dose for future clinical development by studying how the drug affects the body and how the body processes it. The study has two parts Part 1 involves gradually increasing doses of IMP1734 given as a daily oral tablet to identify the highest safe dose or maximum achievable dose. This includes testing the drug alone and in combination with other treatments for specific cancers like metastatic prostate, ovarian, and breast cancer. Part 2 focuses on refining the dose to find the best amount for future studies. Treatment can last up to three years after the first dose. Participants will be monitored closely with assessments of side effects, blood tests to study drug levels and effects, and evaluations of tumor response using standard criteria. Safety monitoring continues up to 30 days after the last dose. Researchers measure how well the drug is tolerated and its impact on the cancer over time. The total participation may extend up to three years, with ongoing evaluations during this period.

Age: 18Years - 89YearsAll GendersPhase 1Phase 2
57 locations
C

Actively Recruiting

Researchers are evaluating the efficacy and safety of rilvegostomig compared to pembrolizumab, both combined with platinum-based doublet chemotherapy, as a first-line treatment for patients with locally advanced or metastatic non-squamous non-small cell lung cancer NSCLC whose tumors express PD-L1 at 1% or higher. This Phase III, randomized, double-blind, global study focuses on patients without certain genetic mutations who have advanced disease not suitable for curative treatment. The trial aims to provide new treatment options for this patient group by comparing two immunotherapy approaches combined with chemotherapy. Participants receive either rilvegostomig or pembrolizumab, each given intravenously on Day 1 of every 21-day cycle, alongside platinum-based doublet chemotherapy carboplatin or cisplatin for up to four cycles. After chemotherapy, patients continue with maintenance monotherapy of their assigned immunotherapy rilvegostomig or pembrolizumab plus pemetrexed given intravenously on Day 1 of each 21-day cycle. This treatment continues until disease progression or unacceptable toxicity. Throughout the study, participants undergo regular assessments including tumor measurements by CT or MRI scans, organ and bone marrow function tests, and monitoring for side effects. Researchers will measure overall survival and progression-free survival for up to approximately six years. Patient-reported outcomes on physical functioning, quality of life, and lung cancer symptoms are also collected. Safety and pharmacokinetics of rilvegostomig are monitored to understand treatment effects and tolerability over the long term.

Age: 18Years +All GendersPhase 3
301 locations
G

Actively Recruiting

Researchers are evaluating the safety and effectiveness of rilvegostomig combined with platinum-based chemotherapy compared to pembrolizumab combined with the same chemotherapy for first-line treatment of patients with locally advanced or metastatic squamous non-small cell lung cancer mNSCLC whose tumors express PD-L1. This Phase III, randomized, double-blind study involves participants whose tumors have a PD-L1 expression of 1% or higher. Participants receive either rilvegostomig or pembrolizumab intravenously on Day 1 of each 21-day cycle, combined with carboplatin and paclitaxel or nab-paclitaxel chemotherapy. Chemotherapy is given for up to 4 cycles, with nab-paclitaxel administered on Days 1, 8, and 15 of each cycle. After the chemotherapy cycles, participants continue with the assigned drug alone. Throughout the study, researchers monitor overall survival and progression-free survival for up to approximately six years. Additional assessments include response rates, duration of response, drug levels in the body, immune reactions to rilvegostomig, and patient-reported physical functioning, quality of life, and lung cancer symptoms. Participants undergo regular evaluations to assess these outcomes and safety throughout the study period.

Age: 18Years +All GendersPhase 3
333 locations

1-10 of 101

1